Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Abstract : HIV-1 can cross the blood-brain barrier (BBB) to penetrate the brain and infect target cells, causing neurocognitive disorders as a result of neuroinflammation and brain damage. The HIV-1 envelope spike gp160 is partially required for viral transcytosis across the BBB endothelium. But do antibodies developing in infected individuals and targeting the HIV-1 gp160 glycoproteins block HIV-1 transcytosis through the BBB? We addressed this issue and discovered that anti-gp160 antibodies do not block HIV-1 transport; instead, free viruses and those in complex with antibodies can transit across BBB endothelial cells. Importantly, we found that only neutralizing antibodies could inhibit posttranscytosis viral infectivity, highlighting their ability to protect susceptible brain cells from HIV-1 infection.
https://hal-pasteur.archives-ouvertes.fr/pasteur-03246667 Contributor : Philippe AfonsoConnect in order to contact the contributor Submitted on : Wednesday, June 2, 2021 - 2:51:43 PM Last modification on : Thursday, April 14, 2022 - 5:12:01 PM Long-term archiving on: : Friday, September 3, 2021 - 7:28:59 PM
Valérie Lorin, Anne Danckaert, Françoise Porrot, Olivier Schwartz, Philippe Afonso, et al.. Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier. mBio, American Society for Microbiology, 2020, 11 (5), pp.e02424-20. ⟨10.1128/mBio.02424-20⟩. ⟨pasteur-03246667⟩